doi:10.3969/j.issn.1004-583X.2024.04.012

Abstract

CLC Number:

R739.9

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.04.012

https://huicui.hebmu.edu.cn/EN/Y2024/V39/I4/363

References 68

[1]	Mahajan A, Brunson A, Adesina O, et al. The incidence of cancer-associated thrombosis is increasing over time[J]. Blood Adv, 2022, 6(1):307-320.
[2]	Girardi L, Wang TF, Ageno W, et al. Updates in the incidence, pathogenesis, and management of cancer and venous thromboembolism[J]. Arterioscler Thromb Vasc Biol, 2023, 43(6):824-831. doi: 10.1161/ATVBAHA.123.318779 pmid: 37139840
[3]	Pavlovic D, Niciforovic D, Markovic M, et al. Cancer-associated thrombosis: Epidemiology, pathophysiological mechanisms, treatment, and risk assessment[J]. Clin Med Insights: Oncol, 2023, 17:1-14.
[4]	Eichinger S. Cancer associated thrombosis: Rrisk factors and outcomes[J]. Thromb Res, 2016, 140(Suppl 1):S12-S17.
[5]	Petrelli F, Cabiddu M, Borgonovo K, et al. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: A meta-analysis of randomized clinical trials[J]. Ann Oncol, 2012, 23(7):1672-1679. doi: 10.1093/annonc/mdr592 pmid: 22241897
[6]	Deschênes-Simard X, Richard C, Galland L, et al. Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study[J]. Thromb Res, 2021, 205(9):29-39.
[7]	Grover SP, Hisada YM, Kasthuri RS, et al. Cancer therapy-associated thrombosis[J]. Arterioscler Thromb Vasc Biol, 2021, 41(4):1291-1305. doi: 10.1161/ATVBAHA.120.314378 pmid: 33567864
[8]	Sussman TA, Li H, Hobbs B, et al. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival[J]. J Immunother Cancer, 2021, 9(1):e001719.
[9]	Tawil N, Mohammadnia A, Rak J. Oncogenes and cancer associated thrombosis: What can we learn from single cell genomics about risks and mechanisms?[J]. Front Med (Lausanne), 2023, 10:1252417.
[10]	da Costa WL Jr, Guffey D, Oluyomi A, et al. Patterns of venous thromboembolism risk, treatment, and outcomes among patients with cancer from uninsured and vulnerable populations[J]. Am J Hematol, 2022, 97(8):1044-1054. doi: 10.1002/ajh.26623 pmid: 35638475
[11]	Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis[J]. JAMA, 2005, 293(6):715-722. doi: 10.1001/jama.293.6.715 pmid: 15701913
[12]	Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers[J]. Arch Intern Med, 2006, 166(4):458-464. doi: 10.1001/archinte.166.4.458 pmid: 16505267
[13]	Cronin-Fenton DP, Sondergaard F, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: A population-based cohort study in Denmark, 1997-2006[J]. Br J Cancer, 2010, 103(7):947-953.
[14]	Blom JW, Vanderschoot JP, Oostindier MJ, et al. Incidence of venous thrombosis in a large cohort of 66, 329 cancer patients: Results of a record linkage study[J]. J Thromb Haemost, 2006, 4(3):529-535. doi: 10.1111/j.1538-7836.2006.01804.x pmid: 16460435
[15]	Ahlbrecht J, Dickmann B, Ay C, et al. Tumor grade is associated with venous thromboembolism in patients with cancer: Results from the Vienna Cancer and Thrombosis Study[J]. J Clin Oncol, 2012, 30(31):3870-3875. doi: 10.1200/JCO.2011.40.1810 pmid: 23008313
[16]	Rogers MA, Levine DA, Blumberg N, et al. Triggers of hospitalization for venous thromboembolism[J]. Circulation, 2012, 125(17):2092-2099. doi: 10.1161/CIRCULATIONAHA.111.084467 pmid: 22474264
[17]	Li H, Tian Y, Niu H, et al. Derivation, validation and assessment of a novel nomogram-based risk assessment model for venous thromboembolism in hospitalized patients with lung cancer: A retrospective case control study[J]. Front Oncol, 2022, 12:988287.
[18]	Li Z, Zhang G, Zhang M, et al. Development and validation of a risk score for prediction of venous thromboembolism in patients with lung cancer[J]. Clin Appl Thromb Hemost, 2020, 26:1-10.
[19]	Wang P, He L, Yuan Q, et al. Risk factors for peripherally inserted central catheter-related venous thrombosis in adult patients with cancer[J]. Thromb J, 2024, 22(1):6. doi: 10.1186/s12959-023-00574-4 pmid: 38178101
[20]	Starling N, Rao S, Cunningham D, et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: A report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group[J]. J Clin Oncol, 2009, 27(23):3786-3793. doi: 10.1200/JCO.2008.19.4274 pmid: 19398575
[21]	Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis[J]. JAMA, 2008, 300(19):2277-2285. doi: 10.1001/jama.2008.656 pmid: 19017914
[22]	Icht O, Darzi N, Shimony S, et al. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors[J]. J Thromb Haemost, 2021, 19(5):1250-1258. doi: 10.1111/jth.15272 pmid: 33605020
[23]	Kewan T, Ko T, Flores M, et al. Prognostic impact and risk factors of cancer-associated thrombosis events in stage-IV cancer patients treated with immune checkpoint inhibitors[J]. Eur J Haematol, 2021, 106(5):682-688. doi: 10.1111/ejh.13598 pmid: 33565130
[24]	Moik F, Chan WE, Wiedemann S, et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy[J]. Blood, 2021, 137(12):1669-1678. doi: 10.1182/blood.2020007878 pmid: 33067632
[25]	Adelborg K, Corraini P, Darvalics B, et al. Risk of thromboembolic and bleeding outcomes following hematological cancers: A Danish population-based cohort study[J]. J Thromb Haemost, 2019, 17(8):1305-1318. doi: 10.1111/jth.14475 pmid: 31054195
[26]	Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancer-associated venous thrombosis[J]. Blood, 2013, 122(10):1712-1723. doi: 10.1182/blood-2013-04-460121 pmid: 23908465
[27]	Ageno W, Haas S, Weitz JI, et al. Upper extremity DVT versus lower extremity DVT: perspectives from the GARFIELD-VTE registry[J]. Thromb Haemost, 2019, 119(8):1365-1372.
[28]	Riva N, Ageno W. Cerebral and splanchnic vein thrombosis: Advances, challenges, and unanswered questions[J]. J Clin Med, 2020, 9(3):743.
[29]	O'Connell C. How I treat incidental pulmonary embolism[J]. Blood, 2015, 125(12):1877-2009. doi: 10.1182/blood-2014-08-551879 pmid: 25533036
[30]	Riva N, Ageno W, Schulman S, et al. Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: A multicentre, international prospective registry[J]. Lancet Haematol, 2016, 3(6):e267-275.
[31]	Lim W, Le Gal G, Bates SM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: Diagnosis of venous thromboembolism[J]. Blood Adv, 2018, 2(22):3226-3256. doi: 10.1182/bloodadvances.2018024828 pmid: 30482764
[32]	Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)[J]. Eur Heart J, 2020, 41(4):543-603. doi: 10.1093/eurheartj/ehz405 pmid: 31504429
[33]	Moik F, Ay C, Pabinger I. Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: Past, present and future[J]. Thromb Res, 2020, 191(Suppl 1):S3-S11.
[34]	Wauthier L, Favresse J, Hardy M, et al. D-dimer testing: A narrative review[J]. Adv Clin Chem, 2023, 114(3):151-223.
[35]	Mulder FI, Candeloro M, Kamphuisen PW, et al. The Khorana score for prediction of venous thromboembolism in cancer patients: A systematic review and meta-analysis[J]. Haematologica, 2019, 104(6):1277-1287. doi: 10.3324/haematol.2018.209114 pmid: 30606788
[36]	Khorana AA. Risk assessment for cancer-associated VTE: Diversifying the evidence base[J]. JACC Asia, 2021, 1(2):271-273. doi: 10.1016/j.jacasi.2021.07.007 pmid: 36338160
[37]	Parker A, Peterson E, Lee AYY, et al. Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer[J]. J Thromb Haemost, 2018, 16(7):1321-1326. doi: 10.1111/jth.14139 pmid: 29733498
[38]	Nishimura A, Ikeda Y. Predicting the incidence of venous thromboembolism using the Khorana score: A Literature Review[J]. Yakugaku Zasshi, 2021, 141(4):611-622. doi: 10.1248/yakushi.20-00228 pmid: 33790126
[39]	Verso M, Agnelli G, Barni S, et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: The Protecht score[J]. Intern Emerg Med, 2012, 7(3):291-292. doi: 10.1007/s11739-012-0784-y pmid: 22547369
[40]	Pelzer U, Sinn M, Stieler J, et al. Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?[J]. Dtsch Med Wochenschr, 2013, 138(41):2084-2088.
[41]	Cella CA, Di Minno G, Carlomagno C, et al. Preventing venous thromboembolism in ambulatory cancer patients: The ONKOTEV study[J]. Oncologist, 2017, 22(5):601-608. doi: 10.1634/theoncologist.2016-0246 pmid: 28424324
[42]	Xiong W, Zhao Y, Du H, et al. Optimal authoritative risk assessment score of cancer-associated venous thromboembolism for hospitalized medical patients with lung cancer[J]. Thromb J, 2021, 19(1):95. doi: 10.1186/s12959-021-00339-x pmid: 34863189
[43]	Gerotziafas GT, Taher A, Abdel-Razeq H, et al. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: The prospective COMPASS-cancer-associated thrombosis study[J]. Oncologist, 2017, 22(10):1222-1231. doi: 10.1634/theoncologist.2016-0414 pmid: 28550032
[44]	Abdel-Razeq H, Sharaf B, Al-Jaghbeer MJ, et al. COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study[J]. J Thromb Thrombolysis, 2023, 56(3):447-453.
[45]	van Es N, Kraaijpoel N, Klok FA, et al. The original and simplified Wells rules and age-adjusted D-dimer testing to rule out pulmonary embolism: An individual patient data meta-analysis[J]. J Thromb Haemost, 2017, 15(4):678-684. doi: 10.1111/jth.13630 pmid: 28106338
[46]	Young MD, Daniels AH, Evangelista PT, et al. Predicting pulmonary embolus in orthopedic trauma patients using the Wells score[J]. Orthopedics, 2013, 36(5):e642-647.
[47]	Qin X, Gao X, Yang Y, et al. Developing a risk assessment tool for cancer-related venous thrombosis in China: A modified Delphi-analytic hierarchy process study[J]. BMC Cancer. 2024, 24(1):120. doi: 10.1186/s12885-024-11877-8 pmid: 38263026
[48]	Farge D, Frere C, Connors JM, et al. International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19[J]. Lancet Oncol, 2022, 23(7):e334-347. doi: 10.1016/S1470-2045(22)00160-7 pmid: 35772465
[49]	Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer[J]. N Engl J Med, 2003, 349(2):146-153.
[50]	Stevens SM, Woller SC, Baumann Kreuziger L, et al. Executive summary: Antithrombotic therapy for VTE disease: Second update of the CHEST guideline and expert panel report[J]. Chest, 2021, 160(6):2247-2259. doi: 10.1016/j.chest.2021.07.056 pmid: 34352279
[51]	Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO clinical practice guideline[J]. Ann Oncol, 2023, 34(5):452-467. doi: 10.1016/j.annonc.2022.12.014 pmid: 36638869
[52]	Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report[J]. Chest, 2016, 149(2):315-352. doi: S0012-3692(15)00335-9 pmid: 26867832
[53]	Chen DY, Tseng CN, Hsieh MJ, et al. Comparison between non-vitamin k antagonist oral anticoagulants and low-molecular-weight heparin in Asian individuals with cancer-associated venous thromboembolism[J]. JAMA Netw Open, 2021, 4(2):e2036304.
[54]	Schrag D, Uno H, Rosovsky R, et al. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: A randomized clinical trial[J]. JAMA, 2023, 329(22):1924-1933. doi: 10.1001/jama.2023.7843 pmid: 37266947
[55]	Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism[J]. N Engl J Med, 2018, 378(7):615-624.
[56]	Jain A, Amira M, Manoharan S, et al. Role of direct oral anticoagulants in gastrointestinal cancer associated thrombosis “practical issues in clinical practice”-narrative review[J]. Ann Palliat Med, 2021, 10(9):10053-10061.
[57]	Guan T, Laguna A, Soares A, et al. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies[J]. J Thromb Thrombolysis, 2023, 56(3):439-446.
[58]	Planquette B, Bertoletti L, Charles-Nelson A, et al. Rivaroxaban vs Dalteparin in cancer-associated thromboembolism: A randomized trial[J]. Chest, 2022, 161(3):781-790.
[59]	Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D)[J]. J Clin Oncol, 2018, 36(20):2017-2023. doi: 10.1200/JCO.2018.78.8034 pmid: 29746227
[60]	Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer[J]. N Engl J Med, 2020, 382(17):1599-1607.
[61]	McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial[J]. J Thromb Haemost, 2020, 18(2):411-421. doi: 10.1111/jth.14662 pmid: 31630479
[62]	Lutsey PL, Zakai NA. Epidemiology and prevention of venous thromboembolism[J]. Nat Rev Cardiol, 2023, 20(4):248-262.
[63]	Oleksiuk-Bójko M, Lisowska A. Venous thromboembolism: Why is it still a significant health problem?[J]. Adv Med Sci, 2023, 68(1):10-20.
[64]	Mulder FI, Horvath-Puho E, van Es N, et al. Venous thromboembolism in cancer patients: A population-based cohort study[J]. Blood, 2021, 137(14):1959-1969. doi: 10.1182/blood.2020007338 pmid: 33171494
[65]	Alcalay A, Wun T, Khatri V, et al. Venous thromboembolism in patients with colorectal cancer: Incidence and effect on survival[J]. J Clin Oncol, 2006, 24(7):1112-1118. pmid: 16505431
[66]	Roopkumar J, Swaidani S, Kim AS, et al. Increased incidence of venous thromboembolism with cancer immunotherapy[J]. Med (NY), 2021, 2(4):423-434.
[67]	Rondon AMR, Kroone C, Kapteijn MY, et al. Role of tissue factor in tumor progression and cancer-associated thrombosis[J]. Semin Thromb Hemost, 2019, 45(4):396-412. doi: 10.1055/s-0039-1687895 pmid: 31096312
[68]	Noble S, Nelson A, Scott J, et al. Patient experience of living with cancer-associated thrombosis in Canada (PELICANADA)[J]. Res Pract Thromb Haemost, 2019, 4(1):154-160.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 68

Related Articles 6

Recommended Articles

Metrics

Comments

[1]	Ye Qian, Ling Zhai, Liu Shenxiang, Lu Guotao, Yin Xudong. Meta analysis on effects of glucocorticoid on the immunotherapy of advanced cancer [J]. Clinical Focus, 2022, 37(7): 591-598.
[2]	. [J]. Clinical Focus, 2022, 37(3): 279-284.
[3]	LIU Bo-ru;WANG Ren-sheng. Spiral CT differential diagnosis of non thyroid-derived tumor in neck of elderly patients [J]. Clinical Focus, 2014, 29(8): 885-887.
[4]	ZHAO Jing-hui;ZHANG Lun;GU Feng;MA Yong-jie;FU Li;HAO Xi-shan. Influence of STAT3 expression on cisplatin sensitivity in head and neck squamous cell carcinoma [J]. CLINICAL FOCUS, 2009, 24(15): 1320-0.
[5]	. [J]. CLINICAL FOCUS, 2007, 22(22): 1605-1605.
[6]	. [J]. CLINICAL FOCUS, 2004, 19(16): 957-957.